Skip to content
Peptigraph home

How to Inject CJC-1295: Sites, Syringes and Steps

Where to inject CJC-1295, which syringe to use, how to read units and the hygiene steps that prevent infection.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGHRH analogUpdated
This is a general guide to subcutaneous injection, not a substitute for being shown by a nurse, pharmacist or doctor.

Injection sites

Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.

  • Belly: at least 2 inches (5 cm) away from the navel.
  • Front and outer thighs.
  • Back of the upper arms, if someone else can reach it.
  • Rotate sites each time and avoid skin that is bruised, scarred or irritated.

Syringe and needle

U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for CJC-1295 in studies: not reported in study abstracts (PubMed search, 11 Oct 2026).

How to read an insulin syringe

Step by step

  1. 1Wash your handsUse soap and water, and work on a clean surface.
  2. 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
  3. 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
  4. 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
  5. 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
  6. 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
How to reconstitute a peptide vial

How CJC-1295 was given in the human studies

Randomised, placebo-controlled trials in healthy adults gave CJC-1295 subcutaneously, as single ascending doses in the first and as repeated weekly or biweekly doses in the second.[6]

The trial estimated the half-life of CJC-1295 at 5.8-8.1 days.[6]

In rats, CJC-1295, a GHRH analogue with an added albumin-reactive group, was still present in plasma beyond 72 hours.[7]

The review describes CJC-1295 as a synthetic GHRH analog that binds covalently to albumin after injection, which extends its half-life and duration of action.[8]

What those injections changed, and what was reported as safety

After repeated doses, IGF-I levels stayed above baseline for up to 28 days. No serious adverse reactions were reported.[6]

Participants were healthy adults aged 21-61.[6]

Regulatory text

Drugs@FDA returns no match for CJC-1295, so no approved product or label exists to set site, storage or technique.[9]

WADA's prohibited list names CJC-1295 among its GHRH analogues.[10]

Common questions

Where do you inject CJC-1295?

The trial abstracts say subcutaneous without naming a body site, and no label exists to specify one.[6]

What syringe is used for CJC-1295?

Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.

How often is CJC-1295 injected?

The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.

How long does CJC-1295 last?

The long-acting form was estimated at 5.8-8.1 days in healthy adults.[6]

More on CJC-1295

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  6. 6Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  7. 7Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.Endocrinology · 2005PMID 15817669Accessed 2 Oct 2026
  8. 8Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
  9. 9Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  10. 10World Anti-Doping Code International Standard Prohibited List 2026 (in effect 1 January 2026)World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026

Found an error? Report a correction.